Abstract:Molecular targeted therapy represented by EGFR tyrosine kinase inhibitors (TKIs) based on genotyping has become a paradigm for precision management of NSCLC. To realize detection and monitoring of EGFR activating and resistance mutations during EGFR TKI therapy, it is important to access tumor samples at different time points. However, this is extremely challenging in patients with lung cancer. Even with access to tumor biopsy specimens, the spatial and temporal heterogeneity of EGFR mutations in NSCLC complicate interpretation of test results. Liquid biopsy has played a prominent role in dynamic and quantitative detection by conquering the difficulty of repeat tissue biopsies and intratumor genetic heterogeneity.1Gerlinger M. Rowan A.J. Horswell S. et al.Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.N Engl J Med. 2012; 366: 883-892Crossref PubMed Scopus (5750) Google Scholar, 2Chan K.C. Jiang P. Zheng Y.W. et al.Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing.Clin Chem. 2013; 59: 211-224Crossref PubMed Scopus (398) Google Scholar However, is current evidence sufficient to support using EGFR mutation detection assays based on liquid biopsy in routine clinical practice? Throughout serial studies on liquid biopsy in recent years, detecting EGFR activating mutations by using circulating tumor DNA (ctDNA) in peripheral blood has been demonstrated to be feasible and reliable for patients with advanced NSCLC, with consistency rates ranging from 78% to 95%, sensitivity rates from 63% to 82%, specificity rates from 92% to 100%, and comparable predictive power to predict EGFR TKIs responses comparable to that of tissue-based detection.3Bai H. Mao L. Wang H.S. et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.J Clin Oncol. 2009; 27: 2653-2659Crossref PubMed Scopus (273) Google Scholar, 4Mok T. Wu Y.L. Lee J.S. et al.Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy.Clin Cancer Res. 2015; 21: 3196-3203Crossref PubMed Scopus (393) Google Scholar, 5Douillard J.Y. Ostoros G. Cobo M. et al.Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.J Thorac Oncol. 2014; 9: 1345-1353Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar, 6Qiu M. Wang J. Xu Y. et al.Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.Cancer Epidemiol Biomarkers Prev. 2015; 24: 206-212Crossref PubMed Scopus (146) Google Scholar On the basis of this evidence, the European and Chinese instructions for gefitinib use have been amended to “plasma ctDNA may be used for EGFR mutation detection when tumor tissues are unavailable.” However, most evidence provided in literature has been from single-center or multicenter controlled clinical studies, which raises the issue of whether such an approach is applicable in routine clinical practice. In the current issue of the Journal of Thoracic Oncology, Reck et al. reported a large, multicenter (in Europe and Japan), noninterventional diagnostic study intended to investigate the utility of plasma ctDNA EGFR mutation testing in a real-world diagnostic setting (the ASSESS study).7Reck M. Hagiwara K. Han B. et al.ctDNA determination of EGFR mutation status in European and Japanese patients with advanced NSCLC: the ASSESS study.J Thorac Oncol. 2016; 11: 1682-1689Abstract Full Text Full Text PDF Scopus (140) Google Scholar They observed that the concordance of mutation status is 89% (sensitivity 46%, specificity 97%, positive predictive value [PV] 78%, and negative PV 90%) in 1162 matched plasma ctDNA and tissue samples. Compared with the results of previous studies on ctDNA-based EGFR mutation detection,3Bai H. Mao L. Wang H.S. et al.Epidermal growth factor receptor mutations in plasma DNA samples predict tumor response in Chinese patients with stages IIIB to IV non-small-cell lung cancer.J Clin Oncol. 2009; 27: 2653-2659Crossref PubMed Scopus (273) Google Scholar, 4Mok T. Wu Y.L. Lee J.S. et al.Detection and dynamic changes of EGFR mutations from circulating tumor DNA as a predictor of survival outcomes in NSCLC patients treated with first-line intercalated erlotinib and chemotherapy.Clin Cancer Res. 2015; 21: 3196-3203Crossref PubMed Scopus (393) Google Scholar, 5Douillard J.Y. Ostoros G. Cobo M. et al.Gefitinib treatment in EGFR mutated Caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status.J Thorac Oncol. 2014; 9: 1345-1353Abstract Full Text Full Text PDF PubMed Scopus (383) Google Scholar, 6Qiu M. Wang J. Xu Y. et al.Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.Cancer Epidemiol Biomarkers Prev. 2015; 24: 206-212Crossref PubMed Scopus (146) Google Scholar this study presented lower sensitivity, lower PV, and a higher false-negative rate. It is possible that the use of multiple detecting methods, including the QIAGNE therascreen EGFR mutation test (Qiagen, Hilden, Germany), Roche cobas EGFR mutation test (Roche Molecular Systems, Pleasanton, CA), and peptide nucleic acid–locked nucleic acid for EGFR mutation analysis, in this study might have contributed to the inferior performance because these technologies have different quality control systems and diverse detection sensitivities. Other factors such as the methods used to obtain tumor samples (surgical resection, biopsy, or cytologic examination), the location of tumors (primary versus metastatic site), the time point of sample collection (fresh versus stored samples), and disease staging (advanced versus locally advanced NSCLC) could all affect the results. In addition, this study was limited by the fact that it was merely a molecular epidemiological investigation and did not include information on the treatment efficacy of EGFR TKIs, so that EGFR mutation status in ctDNA could not be correlated with the clinical outcome of EGFR TKIs. However, the large sample size helped to demonstrate the challenges of plasma ctDNA detection in the real world, suggesting that the standardization and optimization of sample collection, storage, DNA isolation, and mutation detection are factors vital to ensuring high sensitivity, specificity, and predictive accuracy of ctDNA detection for EGFR mutation. T790M mutation is the most common mechanism of resistance to EGFR TKIs,8Yu H.A. Arcila M.E. Rekhtman N. et al.Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.Clin Cancer Res. 2013; 19: 2240-2247Crossref PubMed Scopus (1825) Google Scholar and multiple studies have demonstrated that T790M mutation detection in plasma ctDNA possessed excellent sensitivity, specificity, and predictive accuracy in relation to third-generation TKIs, such as AZD9291 and CO1686, compared with tissue samples from repeat biopsies.9Thress K.S. Brant R. Carr T.H. et al.EGFR mutation detection in ctDNA from NSCLC patient plasma: a cross-platform comparison of leading technologies to support the clinical development of AZD9291.Lung Cancer. 2015; 90: 509-515Abstract Full Text Full Text PDF PubMed Scopus (405) Google Scholar, 10Karlovich C. Goldman J.W. Sun J.M. et al.Assessment of EGFR mutation status in matched plasma and tumor tissue of NSCLC patients from a phase I study of rociletinib (CO-1686).Clin Cancer Res. 2016; 22: 2386-2395Crossref Scopus (160) Google Scholar These results impelled the U.S. Food and Drug Administration's recent approval of the cobas EGFR Mutation Test v 2 (Roche Molecular Systems), which is specifically designed to detect T790M mutations in the blood of patients with NSCLC, as a companion diagnostic test, which is a testament to the application of liquid biopsies in the clinical setting. Besides plasma ctDNA, urine may also be used as a biological specimen for genetic testing. In this issue of the Journal of Thoracic Oncology, Reckamp et al. reported for the first time that T790M mutation in patients with metastatic lung adenocarcinoma treated by EGFR TKIs could be detected in urine. In this study, EGFR activating and T790M mutations in paired tumor tissues and ctDNA from blood and urine samples were analyzed through the hypersensitive next-generation sequencing technique, and the high sensitivity, specificity, and predictive accuracy of T790M mutation in urine ctDNA to third-generation TKIs were presented, especially when urine volume reached more than 90 mL. This is clinically significant because testing of urine ctDNA provides a truly noninvasive and easy to self-manage alternative to tissue biopsy for detection of the T790M mutation status of patients with advanced NSCLC.11Reckamp K.L. Melnikova V.O. Karlovich C. et al.A highly sensitive and quantitative test platform for detection of NSCLC EGFR mutations in urine and plasma.J Thoracic Oncol. 2016; 11: 1690-1700Abstract Full Text Full Text PDF Scopus (228) Google Scholar In addition, the longitudinally dynamic alteration of the T790M signal in urine correlated with tumor shrinkage was observed in a subset of nine patients receiving treatment with rociletinib, and similar results have been reported in studies involving plasma ctDNA detection. These results suggest that urine-based genetic analysis may be used to monitor patients’ response and foresee the appearance of novel resistance genes before clinical or radiological progression. If the cutoff value of “molecular resistance” in urine or plasma can be determined in further study, the antiresistance strategy will switch from treatment to prevention, which may bring patients a greater survival benefit. The other strength of this study is that 12 T790M-positive patients who were not detected through tumor tissue samples were identified by using urine and plasma samples, supporting the evidence that liquid biopsy has advantages for overcoming the heterogeneity of repeat biopsy tissue assays. This also raises the question of whether liquid biopsy is more “precise” than tumor biopsies, especially when liquid biopsy is used for monitoring of resistance related genes change. Further studies will be needed to support the hypothesis. The detection and monitoring of relapse and metastasis of early-stage NSCLC after radical resection at the cytological and molecular genetic levels have become hot issues in recent years. As another vector in peripheral blood, the circulating tumor cell (CTC) appears to be an excellent model to investigate tumor recurrence and metastasis.12Haber D.A. Velculescu V.E. Blood-based analyses of cancer: circulating tumor cells and circulating tumor DNA.Cancer Discov. 2014; 4: 650-661Crossref PubMed Scopus (494) Google Scholar Previous research focused mainly on determining the relationship between alteration of CTC count after treatment and patients' outcome in advanced cancers such as breast cancer and prostate cancer.13Danila D.C. Heller G. Gignac G.A. et al.Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer.Clin Cancer Res. 2007; 13: 7053-7058Crossref PubMed Scopus (551) Google Scholar, 14Hayes D.F. Cristofanilli M. Budd G.T. et al.Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival.Clin Cancer Res. 2006; 12: 4218-4224Crossref PubMed Scopus (827) Google Scholar Recent studies of single–driver gene or genome sequencing in a single CTC or bulk CTCs extends the realm of liquid biopsy–based research.15Maheswaran S. Sequist L.V. Nagrath S. et al.Detection of mutations in EGFR in circulating lung-cancer cells.N Engl J Med. 2008; 359: 366-377Crossref PubMed Scopus (1476) Google Scholar, 16Lohr J.G. Adalsteinsson V.A. Cibulskis K. et al.Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer.Nat Biotechnol. 2014; 32: 479-484Crossref PubMed Scopus (428) Google Scholar, 17Krebs M.G. Metcalf R.L. Carter L. et al.Molecular analysis of circulating tumour cells-biology and biomarkers.Nat Rev Clin Oncol. 2014; 11: 129-144Crossref PubMed Scopus (473) Google Scholar However, highly efficient acquisition of CTCs is a cornerstone for subsequent analysis of cancer-specific genomic alteration. Crosbie et al.18Crosbie P.A.J. Shah R. Krysiak P. et al.Circulating tumor cells detected in the tumor-draining pulmonary vein are associated with disease recurrence after surgical resection of NSCLC.J Thoracic Oncol. 2016; 11: 1793-1797Abstract Full Text Full Text PDF Scopus (62) Google Scholar analyzed the correlation between tumor recurrence and metastasis and CTC enumeration (a single cell versus a cluster) in tumor-draining pulmonary veins and peripheral blood in early lung cancer. They found that pulmonary vein CTC count was significantly higher when compared with that in matched peripheral vein samples. Pulmonary vein and peripheral vein CTC counts were both significant risk factors for tumor recurrence. Pulmonary vein circulating tumor microemboli or two or more CTCs per 7.5 mL of peripheral blood were related to high-risk for both tumor recurrence and death. However, it is too early to draw conclusions on account of the limited sample size. Furthermore, the results of this study were affected by the fact that it involved only the analysis of CTC quantity and did not examine the role that hotspot genetic alteration may play in recurrence and metastasis of lung cancer. Notwithstanding, Crosbie et al. provide the evidence for conducting additional large-scale, multicenter studies to ascertain whether CTCs or CTM in pulmonary veins represent the cluster of cells with the highest capacity for invasion and metastasis. In summary, after nearly a decade of exploration and development, detection of EGFR activating and resistance mutations on the basis of plasma ctDNA has gradually been applied in clinical practice of NSCLC, finally becoming the prerequisite and basis for accomplishing precision management of lung cancer. Urinary DNA– and CTC-based genetic detections will enrich the utility of liquid biopsy after undergoing large-sample and multicenter studies. The three studies published in this issue of Journal of Thoracic Oncology have added evidence from different perspectives for clinical utilization of liquid biopsy. A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and PlasmaJournal of Thoracic OncologyVol. 11Issue 10PreviewIn approximately 60% of patients with NSCLC who are receiving EGFR tyrosine kinase inhibitors, resistance develops through the acquisition of EGFR T790M mutation. We aimed to demonstrate that a highly sensitive and quantitative next-generation sequencing analysis of EGFR mutations from urine and plasma specimens is feasible. Full-Text PDF Open AccessCirculating Tumor Cells Detected in the Tumor-Draining Pulmonary Vein Are Associated with Disease Recurrence after Surgical Resection of NSCLCJournal of Thoracic OncologyVol. 11Issue 10PreviewTumor recurrence after surgical resection of NSCLC obstructs long-term disease-free survival in approximately 50% of cases. Our data suggest that combining circulating tumor cell enumeration (as single cells or clusters) in tumor-draining pulmonary vein and peripheral blood (assessed by CellSearch) at the time of NSCLC surgery better identifies those patients at higher risk for lung cancer recurrence than does peripheral circulating tumor cell number alone. Full-Text PDF Open AccessctDNA Determination of EGFR Mutation Status in European and Japanese Patients with Advanced NSCLC: The ASSESS StudyJournal of Thoracic OncologyVol. 11Issue 10PreviewTo offer patients with EGFR mutation–positive advanced NSCLC appropriate EGFR tyrosine kinase inhibitor treatment, mutation testing of tumor samples is required. However, tissue/cytologic samples are not always available or evaluable. The large, noninterventional diagnostic ASSESS study (NCT01785888) evaluated the utility of circulating free tumor-derived DNA (ctDNA) from plasma for EGFR mutation testing. Full-Text PDF Open Access

Abstract 2555: Real-world data analysis of comprehensive genomic profiling using plasma samples from non-small cell lung cancer patients

Abstract 5891: Plasma-based BDA-NGS Test Holds Potential in Circulating Nucleic Acid Based Oncogenic Aberration Detection

Abstract 6457: The real-world data of comprehensive genomic profiling tests with tissue specimens from lung cancer patients in Japan

P2.15-33 Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced NSCLC: What Happens after Panel Testing by NGS?

Evaluation of Liquid Biopsies for Molecular Profiling in Patients (pts) with Advanced Non-Small Cell Lung Cancer (NSCLC): What Happens after Panel Testing by Next Generation Sequencing (NGS)?

Abstract 5581: Clinical validation of a highly sensitive assay to detect mutations in plasma from advanced lung adenocarcinoma patients

Abstract 3380: Use of liquid biopsy for detection of pathogenic variants in cell-free tumor DNA from patients with precursor lesions and colorectal cancer

Abstract 2410: Comparative genomic profiling of unresectable NSCLC patients in the U.S. and China using a globally harmonized liquid biopsy assay platform

Liquid Biopsies Using Pleural Effusion-Derived Exosomal DNA in Advanced Lung Adenocarcinoma.

Liquid biopsy in the clinic: A prospective study of plasma circulating tumor DNA (ctDNA) next generation sequencing (NGS) in patients with advanced non-small cell lung cancers to match targeted therapy.

Are Liquid Biopsies Ready for Prime Time of Clinical Applications?

Abstract 1992: Improved somatic classification and detection of tumor heterogeneity using ctDNA based liquid biopsy compared to tumor-only tissue in colorectal cancer

Abstract 6132: Exploring genomic complexity in lung cancer at the Tijuana/California border: A real-world perspective through liquid biopsy comprehensive genomic profiling

Abstract 2742: Cross-platform Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Plasma of Patients with Non-Small Cell Lung Carcinoma

Clinical Outcomes in Non-Small-Cell Lung Cancer Patients Treated With EGFR-Tyrosine Kinase Inhibitors and Other Targeted Therapies Based on Tumor Versus Plasma Genomic Profiling

Abstract 3448: A novel liquid biopsy lung cancer detection method using a coverage and fragment end motif machine learning analysis

Abstract 970: Liquid biopsy-informed precision oncology clinical trial to evaluate the utility of ctDNA comprehensive genomic profiling

Abstract LB099: Identifying actionable genomic alterations in non-small cell lung cancer through the analysis of extracellular vesicles in plasma

Real-World Clinical Performance of a DNA-Based Comprehensive Genomic Profiling Assay for Detecting Targetable Fusions in Nonsquamous NSCLC

Abstract 6687: Prevalence of four major gene mutation classes in a survey of ctDNA recovery from early and advanced stage NSCLC

Abstract 6606: Biomarker discovery in non-small-cell lung cancer enabled by deep multi-omics profiling of proteins, metabolites, transcripts, and genes in blood